Lupin recalls two lots of antibiotic drug 'Suprax' in US market

Tags: Lupin, Companies
Drug major Lupin is voluntarily recalling 9,210 bottles of its antibiotic drug Suprax, used to treat bacterial infections, in the US market, according to the US Food and Drug Administration (USFDA).

As per the information available on the USFDA website, Lupin Pharmaceuticals Inc, the US-based unit of the company, is recalling two lots of Suprax as the "product did not meet specification in total impurities at the nine-month stability station".

The company is recalling 4,038 bottles of Suprax in the first lot and 5,172 bottles of the drug in the second lot in the US market, it added.

The nationwide recall has been initiated by the company on January 27 this year.

The recall of the drugs has been initiated under Class-III which FDA defined as "a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences".

When contacted, a Lupin spokesperson said: "This is a voluntary recall initiated on our own and of no business consequence."

Last year also, the Mumbai-based firm had voluntarily recalled 64,368 bottles of Suprax in the US market on account of discolouration.

Suprax contains cefixime, which is a third-generation oral cephalosporin that has an important role in treating common infections.

EDITORIAL OF THE DAY

  • PSU banks can take a lesson from their private peers on disclosures

    The country’s top private lenders ICICI Bank and Axis Bank declared their fourth quarter earnings recently and both stepped up their asset quality d

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Tushar Gandhi

An unexplored side of rural enterprise

What is rural enterprise? Ask this qu­estion and 9 out ...

Rajgopal Nidamboor

Timeless idiom of mindful living

Each of us, according to scholar-historian Felipe Fernandez-Armesto, is familiar ...

Dharmendra Khandal

So, how do we define a 'vermin'?

These days there’s an ongoing debate whether to declare various ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture